What question did this study set out to answer?

To identify prognostic factors affecting outcomes in RRMM patients receiving bispecific antibodies.

December 8, 2025BloodOpen Access

Prognostic value of immunoparesis, lymphopenia, high serum ferritin, and suppression of the non-involved serum free light chains (niFLC) in relapsed and refractory multiple myeloma patients (RRMM) receiving bispecific antibodies

View Full Paper

Ask AI

Bookmark

To identify prognostic factors affecting outcomes in RRMM patients receiving bispecific antibodies.
Retrospective analysis of RRMM patients treated with bispecific antibodies between 2022 and 2025.
Monitored baseline lymphocyte counts and serum ferritin levels for risk assessment.
Evaluated the correlation between niFLC suppression and patient response.
Baseline lymphopenia and elevated ferritin levels were independent predictors of worse progression-free survival.
Median PFS was significantly lower in patients with baseline lymphopenia and high ferritin levels.
68% achieved partial response and 64% achieved very good partial response post-treatment.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Retrospective analysis identifies lymphopenia and other factors predicting poorer progression-free survival in relapsed multiple myeloma treated with bispecific antibodies.

Cite This Study

Castro et al. (2025) studied this question.

synapsesocial.com/papers/69362f714fa91c937236e1c3 https://doi.org/10.1182/blood-2025-5772

View Full Paper

Ask AI

Bookmark

Implication

Retrospective analysis identifies lymphopenia and other factors predicting poorer progression-free survival in relapsed multiple myeloma treated with bispecific antibodies.

Prognostic value of immunoparesis, lymphopenia, high serum ferritin, and suppression of the non-involved serum free light chains (niFLC) in relapsed and refractory multiple myeloma patients (RRMM) receiving bispecific antibodies

Key Points

Discussion

Implication

Cite This Study

Prognostic value of immunoparesis, lymphopenia, high serum ferritin, and suppression of the non-involved serum free light chains (niFLC) in relapsed and refractory multiple myeloma patients (RRMM) receiving bispecific antibodies

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider